Remifentanil-induced hyperalgesia
Conditions
Interventions
Treatment group:Tegileridine Fumarate Injection
Control group:Normal saline
Sponsors
chongqing university cancer hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 75 years; 2.American Society of Anesthesiologists (ASA) physical status classification I to III; 3.Scheduled to undergo elective laparoscopic surgery; 4.Expected surgical duration exceeding 2 hours; 5.Remifentanil administered intraoperatively; 6.Willingness to receive postoperative intravenous patient-controlled analgesia; 7.Voluntary participation with written informed consent obtained;
Exclusion criteria
Exclusion criteria: 1.Patients presenting with severe preoperative comorbidities, including hepatic or renal dysfunction, unstable angina pectoris, severe chronic obstructive pulmonary disease (COPD), concomitant traumatic brain injury, intracranial hypertension, stroke, or a history of myocardial infarction; 2.Pregnant; 3.History of opioid abuse; 4.Patients with psychiatric disorders undergoing long-term antipsychotic therapy; 5.Patients experiencing major intraoperative complications such as hemorrhagic shock or bronchospasm; 6.Patients requiring postoperative admission to the intensive care unit (ICU); 7.Patients diagnosed with peripheral neuropathy; 8.Surgical procedures lasting >=5 hours;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain threshold of the skin surrounding the surgical incision at 24 hours postoperatively;Postoperative 24-hour pain threshold measured on the medial aspect of the non-dominant forearm;extubation time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Romsay scores;QoR-15 scores;Length of stay;Respiratory depression;Postoperative opioid consumption;Postoperative NRS scores;PONV; | — |
Countries
China
Contacts
Public ContactQianyun Pang
chongqing university cancer hospital
Outcome results
None listed